Qure.ai Collects $65 Million in Series D Funding

Qure.ai has compled a $65 million Series D funding round led by Lightspeed and 360 ONE Asset, joined by Merck Global Health Innovation Fund, Kae Capital, Novo Holdings, Health Quad, and TeamFund.

The money will be used to expedite the firm’s expansion into the U.S. market and other geographies, increase investment into foundational AI models, and enable complementary med-tech company acquisitions.

“Qure.ai has become a trusted medical imaging AI partner to hospitals and healthcare organisations around the world. Our work is helping to unlock clinical efficiencies and drive up the standard of care delivered to patients in the focus areas of TB, lung cancer, and stroke,” Qure.ai Co-Founder/CEO Prashant Warier said. “AI helps to overcome healthcare bottlenecks, from imaging reporting backlogs and low screening uptakes to workforce resource constraints, not just in western societies like the U.S. and Europe, but in developing nations too. We also collaborate with half of the top 20 pharma and medtech companies including AstraZeneca, Medtronic, and J&J, to accelerate early diagnosis and timely treatment of diseases. This Series D round is an exciting step forward in our journey and will propel us forward in our mission to reach a billion patients through our solutions.” 
 
Founded in 2016, Qure.ai is striving to make healthcare more accessible and equitable globally. Qure.ai solutions are deployed in over 90 countries across more than 3,000 sites, powering the efficient identification and management of critical diseases. The company has 18 U.S. Food and Drug Administration-cleared indications, and its products are Class IIb certified per EU MDR* regulations. Qure.ai is headquartered in Mumbai, with regional offices in New York, London, and Dubai.
 
“We are excited to back Prashant and his team at Qure.ai, a true leader in AI-driven healthcare diagnostics,” Lightspeed Partner Dev Khare stated. “With diagnostic specificity and sensitivity at levels rivaling radiologists and physicians, Qure is making quality healthcare accessible in the U.S. and Europe as well as globally in Asia, Africa, and Latin America.”
 
“We are thrilled to partner with Qure.ai on its mission to revolutionize patient care for critical conditions like TB, lung cancer, and stroke. We believe that most meaningful impact of AI can be in healthcare and Qure is leading the way in making that a reality,” 360 ONE Asset Fund Manager Tarun Sharma concluded. “Its work on helping detect and diagnose TB in real-time in low-resource and high-disease burden regions across the world has the potential for massive impact. In high mortality disease like lung cancer, by enabling earlier diagnosis and treatment, Qure can be transformational in improving clinical outcomes. We look forward to joining Prashant and his team in the next phase of the growth journey.” 
 
Qure.ai is a breakthrough artificial intelligence (AI) solution provider that is disrupting the radiology ‘status quo’ by enhancing imaging accuracy and improving health outcomes with the assistance of machine-supported tools. Qure.ai taps deep learning technology to provide automated interpretation of radiology exams like X-rays, computed tomography, and ultrasounds scans for time and resource-strapped medical imaging professionals—enabling faster diagnosis and speed to treatment. 

*Regulatory clearances vary by region